Date: 17th & 18th June 2014

Minutes: Final

Guideline Development Group Meeting 10  Type 2 Diabetes
Place: NICE Offices & City Tower, Piccadilly Plaza, Manchester, M1 4BT

Present: Damien Longson (Chair)
         Ian Lewin (IL)
         Sailesh Sankar (SS)
         Maria Cowell (MC)
         Jonathan Roddick (JR)
         Yvonne Johns (YJ)
         Natasha Marsland (NM)
         Prunella Neale (PN)
         Andrew Farmer (AFr)
         Natasha Jacques (NJ)
         Anne Fittock (AF)

Apologies: Amanda Adler (AA)
          Natasha Marsland (NM)
          Sailesh Sankar (SS) (18th June only)
          Maria Cowell (MC)
          Natasha Jacques (NJ) (18th June only)

In attendance:

NICE Staff:

Abitha Senthinathan (AS)
Stephanie Mills (SM)
Mike Heath (MH)
Steven Ward (Sward)
Gabriel Rogers (GR)
Hugh McGuire (HM)
Clifford Middleton (CM)
Sharlene Ting (ST)

Observers:

Paul Crosland | NICE Staff
Day 1 – 17th June 2014

1. DL welcomed the group to the 10th meeting of this GDG. Apologies were received from AA, NM, MC, and from SS and NJ for day 2 of the meeting. All committee members declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all present. The objectives of the day were to look at the evidence for all lines of pharmacological therapy.

IL gave an update on the discussions of the Diabetes Oversight Group.

2. Prior to a progress update on the health economic model for pharmacological therapy, AS presented an overall summary of the results for initial therapy, first intensification of drug treatment and second intensification of drug treatment. The GDG were shown a general picture of what the data suggested to offer context to their later considerations and development of recommendations.

3. SWard presented to the GDG on the progress of the health economics, the advantages and limitations of the model. The GDG offered their views on data points it may also be useful to group or separate to support the modelling.

4. AS presented a full set of results for the network meta-analysis on second intensification of pharmacological therapy. After seeing the dataset, the GDG revisited their draft recommendations in this area to review their terminology and sense check what had been drafted previously.

5. SP spoke to the GDG about her role as the editor and the accompanying tools that will be developed alongside the guideline.

6. SWard continued his presentation on the progress of the health economic modelling.

7. AS went on to present the final results for first intensification of drug treatment. The GDG looked at how connected the networks were and discussed the quality of the evidence including any confounding factors in the picture of results. The GDG agreed the evidence statements and then went on to make draft recommendations.

Day 2 – 18th June 2014

8. GR began day 2 of the meeting by presenting some draft health economic results for second and first intensification of pharmacological therapy. The group considered the emerging picture and potential research recommendations stemming from the work conducted. This work allowed the GDG to sense check the recommendations they had already made.

9. AS presented the final results for initial pharmacological therapy. The GDG discussed the evidence and agreed the evidence statements. GR was able to provide some draft results on the health economics for initial therapy. The GDG drafted some recommendations but wanted to wait for the final results before confirming these.

10. DL thanked the group for their hard work and informed them of the dates of the last GDG meeting in guideline development.

Date, time and venue of the next meeting
Wed 3rd Sept & Thurs 4th Sept 2014 –NICE, Manchester